.jpg)
.png)
Cardiovascular disease (CVD) is the leading cause of death in the U.S.1 There have been many important advances in the treatment of CVD in recent decades. However, not all touted therapies carry the same quality of evidence supporting their use. Chelation therapy is one such treatment that has been controversial since its inception more than half a century ago. Is its use as a treatment for CVD proven or a myth?
Article By:
Massachusetts General Hospital
Boston, MA
Instructor in Medicine
Harvard Medical School
Assistant Physician in Medicine
Massachusetts General Hospital
Boston, MA
Diplomate, American Board of Clinical Lipidology
The global epidemic of type 2 diabetes (T2DM) continues unabated. Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are the most common causes of T2DM-related mortality. More than 90 percent of patients with T2DM are overweight or obese. The pathogenesis of this disorder is heterogenous, but insulin resistance and relative β-cell dysfunction are its key characteristics.
Article By:
Joslin Diabetes Center
Department of Medicine
Harvard Medical School
Boston, MA
William Hazlitt, an 18th century literary critic and philosopher, once said, “When a thing ceases to be a subject of controversy, it ceases to be a subject of interest.”1 If one accepts his premise, then interest in high-density lipoprotein (HDL) shall endure for some time. As far as contemporary medical controversies go, the HDL story is definitely in contention.
Article By:
HDL Apomics
Allenhurst, NJ
Department of Pathology and Laboratory Medicine
University of Cincinnati, College of Medicine
Cincinnati, OH
“He who thinks he knows, doesn’t know. He who knows that he doesn’t know, knows. For in this context, to know is not to know. And not to know is to know.” – Joseph Campbell, The Power of Myth
Article By:
University of Pennsylvania
Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Diplomate, American Board of Clinical Lipidology
Welcome to the Scientific Sessions issue of the LipidSpin — this year sponsored by the Northeast Lipid Association (NELA). We have had a lot of fun putting this issue together, and hope that you will enjoy reading this issue just as much.
Article By:
Instructor in Medicine
Harvard Medical School
Assistant Physician in Medicine
Massachusetts General Hospital
Boston, MA
Diplomate, American Board of Clinical Lipidology
As I near the end of my term as president of the National Lipid Association (NLA), I have so many thoughts about this rewarding experience that I want to share with you. I remember meeting with an ever-smiling Michael Davidson, MD, FNLA, in 2004, who had so much to tell me about this young organization that he thought would be a perfect fit for me.
Article By:
Associate Professor of Medicine
University of Miami School of Medicine
Director, Lipid Clinic and Cardiovascular Risk Reduction Program
Miami, FL
Diplomate, American Board of Clinical Lipidology
The NLA and Foundation of the NLA Recognize Renowned Physician and Researcher Dr. Joseph L. Witztum With Highest Honor, W. Virgil Brown Distinguished Achievement Award
By Carl E. Orringer, MD, FACC; Pamela Bowe Morris, MD, FACC; Donald M. Lloyd-Jones, MD, FACC
The 2016 American College of Cardiology (ACC) Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk
By Carl Orringer, MD, FNLA
The National Lipid Association (NLA) endorses the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk, published by the American College of Cardiology on April 1 in the Journal of the American College of Cardiology. Click here to view the document.